Updates in Retinal Disease Care: Keeping an Eye on Emerging Anti-VEGF Therapies & Improved Outcomes
December 20, 2022
December 20, 2023
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by the Potomac Center for Medical Education and Rockpointe.
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credits™
- Physicians — 1.0 Medical Knowledge ABO MOC points
All other healthcare professionals completing this course will be issued a statement of participation.
I. Welcome and Introduction
II. Current State of Retinal Disease Management
III. Clinical Updates for New and Emerging Retinal Disease Therapies
IV. Q & A Session and Activity Roundup
The intended audience for this educational activity is opthalmologists and clinicians who manage patients with retinal disease.
The prevalence of retinal diseases such as age-related macular degeneration and diabetic macular edema is projected to rise dramatically in the coming decades with an aging population and the increasing prevalence of diabetes.
The availability of anti-vascular endothelial growth factor (VEGF) therapies has significantly improved outcomes for patients with retinal disease for over a decade. However, the need for frequent intravitreal injections required to obtain the best possible patient outcomes with anti-VEGF therapies has added to the patient burden associated with retinal disease management. This also led many clinicians and patients to opt for as-needed dosing intervals guided by optical coherence tomography results, which may be more expedient for patients but has also been associated with worsening of retinal disease and vision loss. Thus, an unmet need persists for more efficacious therapies with increased duration of response to minimize the number of injections required for the many patients with retinal disease. There are newly available therapeutic options, such as the port delivery system with ranibizumab and the dual anti-VEGF, anti-Ang-2 binding faricimab; along with several emerging, novel therapies including sustained-release anti-VEGF formulations, combination anti-VEGFs, and gene therapy.
This program will deliver much-needed, up-to-date information on evidence-based strategies for dosing available anti-VEGF therapies and for integrating newly approved therapies into practice; with reviews of current clinical data from emerging retinal disease therapies.
Upon completion of this activity, participants should be better able to:
- Assess risk/benefits of fixed, frequent dosing intervals versus as-needed dosing intervals for anti-VEGF therapies
- Select anti-VEGF dosing intervals that provide the best potential outcomes for patients with retinal disease
- Assess the safety and efficacy of recently approved and emerging retinal disease therapies
Nancy Holekamp, MD
Director of Retina Services
Pepose Vision Institute
Carl Regillo, MD
Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation Statement
The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABO MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, earns credit toward the Lifelong Learning requirement for the American Board of Opthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit.
Disclosures of Conflicts of Interest
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other relevant professional organizations, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of an accredited continuing education program provided by the Potomac Center for Medical Education are required to disclose to PCME all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by PCME in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by PCME to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by PCME.
The faculty, authors, and content developers reported the following relevant financial relationships with ineligible companies:
- Nancy Holekamp, MD
- Consulting Fee: AGTC, Allergan, Annexon, Apellis, Bayer, Cardinal, Clearside Biosciences, EyePoint, Gemini, Genentech, Gyroscope, Nacuity, NGM, Notal Vision, Novartis, Ocuphire, Outlook Therapeutics, Regeneron, Stealth Biosciences, Thea
- Contracted Research: Gemini, Gyroscope, Genentech, Notal Vision
- Speakers' Bureau: Allergan, Apellis, Genentech, Regeneron, Spark
- Stock Shareholder: Apellis, Gemini
- Stock Options: Nacuity
- Carl Regillo, MD
- Consulting Fee: Adverum, Allergan, Annexon, B & L, Chengdu Kanghong, Clearside, Eyepoint, Genentech, Graybug, Iveric, Kodiac, Lineage, Merck, NGM, Novartis, RegenXBio, Stealth, Thea, Zeiss
- Contracted Research: Adverum, Allergan, Annexon, Astellis, Chengdu Kanghong, Eyepoint, Genentech, Graybug, Iveric, Kodiac, Lineage, NGM, Notal, Novartis, Opthea, Regeneron, RegenXBio
- Stock Shareholder: Iveric, Ocugen
The planners and managers reported the following relevant financial relationships with ineligible companies:
Chad Williamson, MS, MBA, CMPP: Has no relevant financial relationships
The content reviewers reported the following relevant financial relationships with ineligible companies:
Katie Propst, PhD: Has no relevant financial relationships
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Participate in this one-hour-long activity.
- Complete the online post-test and receive a score of ≥ 70%
- Complete the online evaluation.
Certificates will be emailed to the participant.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions please contact email@example.com